Revvity Reports Strong Q3 2026 Results with Raised Full-Year Guidance
Revvity (RVTY) delivered a robust third quarter for fiscal year 2026, reporting pro forma organic revenue growth of 7%, which surpassed management's mid-single-digit expectations. The company saw significant strength in its Life Sciences segment, particularly within reagents and software, while the Diagnostics segment maintained steady performance. Adjusted EPS reached $1.37, beating the midpoint of previous guidance. Driven by broad-based performance across the Americas and Europe, Revvity has raised its full-year organic growth guidance to 5% and increased its operating margin outlook for the third consecutive quarter. The company also demonstrated strong cash flow management, converting 99% of adjusted net income into free cash flow, while successfully reducing leverage following a $500 million debt retirement.
Topics: adjusted eps diagnostics free cash flow life sciences operating margin organic revenue growth